Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in Life-threatening COVID-19
NCT04381052Phase 2Terminated
- Sponsor
- Columbia University
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in coronavirus disease 2019 (COVID-19), sponsored by Columbia University. Started May 2020; status: terminated.
02
Drugs
clazakizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04381052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381052.